Sep 3, 2026 · 42 min
GLP-1 drugs expose the labor market’s obesity penalty
The Hidden Link Between Ozempic & Employment Rates
The episode connects weight-loss medication to employment barriers, then argues that durable health depends more on ordinary habits than endless optimization.
- 1GLP-1 drugs may help some women reenter work while revealing how obesity shapes employment outcomes.
- 2Influencers often turn limited evidence into sweeping health claims that reward novelty over meaningful effect sizes.
- 3Strength, balance, sleep, movement, and social connection offer more practical value than fitness shortcuts or constant optimization.
Don't miss
The hosts connect strength training and balance to the potentially devastating chain of falls, hip fractures, immobility, and declining health in older adults.
The brief
Dick Costolo and Paul Kedrosky begin with Elon Musk and the All-In podcast before turning to a more consequential question: whether GLP-1 drugs are changing employment patterns.
They examine research suggesting weight loss may help some women return to work, while raising uncomfortable questions about obesity-related discrimination and what labor statistics conceal.
The hosts then challenge wellness influencers who inflate thin evidence, arguing that sleep, nutrition, exercise, social connection, and avoiding smoking matter more than novel supplements.
Their strongest practical case is for strength and balance: preserving muscle and reducing fall risk may matter more with age than chasing a single VO2 max score.
The episode ends with a warning that social media and AI can turn sensible fitness into neurosis by constantly inventing new deficiencies, rules, and optimizations.